{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T03:50:39Z","timestamp":1787629839179,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,12]]},"DOI":"10.7759\/cureus.31404","type":"journal-article","created":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T12:55:16Z","timestamp":1668257716000},"source":"Crossref","is-referenced-by-count":2,"title":["Role of Ertugliflozin in the Management of Diabetes Mellitus"],"prefix":"10.7759","author":[{"given":"Manisha","family":"Totade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa  A","family":"Gaidhane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon CP","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, et al.. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020, 383:1425-35. 10.1056\/NEJMoa2004967","journal-title":"N Engl J Med"},{"key":"ref2","unstructured":"Annex 1. summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/steglatro-epar-product-information_en.pdf."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2020-7-4","article-title":"Ertugliflozin in the treatment of type 2 diabetes mellitus","volume":"9","author":"Marrs JC","year":"2020","unstructured":"Marrs JC, Anderson SL. Ertugliflozin in the treatment of type 2 diabetes mellitus. Drugs Context. 2020, 9:10.7573\/dic.2020-7-4","journal-title":"Drugs Context"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2018.1503051","article-title":"Ertugliflozin for treatment of patients with Type 2 diabetes mellitus","volume":"11","author":"Yang J","year":"2018","unstructured":"Yang J. Ertugliflozin for treatment of patients with Type 2 diabetes mellitus. Expert Rev Clin Pharmacol. 2018, 11:747-53. 10.1080\/17512433.2018.1503051","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14074","article-title":"Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: a large multinational cohort study","volume":"22","author":"Birkeland KI","year":"2020","unstructured":"Birkeland KI, Bodegard J, Eriksson JW, et al.. Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: a large multinational cohort study. Diabetes Obes Metab. 2020, 22:1607-18. 10.1111\/dom.14074","journal-title":"Diabetes Obes Metab"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-022-01277-1","article-title":"Prevention of cardiorenal complications with sodium-glucose cotransporter type 2 inhibitors: a narrative review","volume":"13","author":"Botana M","year":"2022","unstructured":"Botana M, Escalada J, Merchante \u00c1, Reyes R, Rozas P. Prevention of cardiorenal complications with sodium-glucose cotransporter type 2 inhibitors: a narrative review. Diabetes Ther. 2022, 13:5-17. 10.1007\/s13300-022-01277-1","journal-title":"Diabetes Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015, 373:2117-28. 10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.117.311588","article-title":"Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors","volume":"122","author":"Scheen AJ","year":"2018","unstructured":"Scheen AJ. Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors. Circ Res. 2018, 122:1439-59. 10.1161\/CIRCRESAHA.117.311588","journal-title":"Circ Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00414-020-02481-z","article-title":"Sudden cardiac death-update","volume":"135","author":"Markwerth P","year":"2021","unstructured":"Markwerth P, Bajanowski T, Tzimas I, Dettmeyer R. Sudden cardiac death-update. Int J Legal Med. 2021, 135:483-95. 10.1007\/s00414-020-02481-z","journal-title":"Int J Legal Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2021.03.028","article-title":"Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials","volume":"18","author":"Fernandes GC","year":"2021","unstructured":"Fernandes GC, Fernandes A, Cardoso R, et al.. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials. Heart Rhythm. 2021, 18:1098-105. 10.1016\/j.hrthm.2021.03.028","journal-title":"Heart Rhythm"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608664","article-title":"Mortality and cardiovascular disease in type 1 and type 2 diabetes","volume":"376","author":"Rawshani A","year":"2017","unstructured":"Rawshani A, Rawshani A, Franz\u00e9n S, et al.. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017, 376:1407-18. 10.1056\/NEJMoa1608664","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm.2018.02.907","article-title":"Cardiorenal outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME trials: a systematic review","volume":"19","author":"Kluger AY","year":"2018","unstructured":"Kluger AY, Tecson KM, Barbin CM, et al.. Cardiorenal outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME trials: a systematic review. Rev Cardiovasc Med. 2018, 19:41-9. 10.31083\/j.rcm.2018.02.907","journal-title":"Rev Cardiovasc Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal B","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al.. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017, 377:644-57. 10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott SD","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al.. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019, 380:347-57. 10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2020-318060","article-title":"Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure","author":"Joshi SS","year":"2021","unstructured":"Joshi SS, Singh T, Newby DE, Singh J. Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure. Heart. 2021, 10.1136\/heartjnl-2020-318060","journal-title":"Heart"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.038881","article-title":"Possible mechanism of hematocrit elevation by sodium-glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects","volume":"139","author":"Sano M","year":"2019","unstructured":"Sano M, Goto S. Possible mechanism of hematocrit elevation by sodium-glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects. Circulation. 2019, 139:1985-7. 10.1161\/CIRCULATIONAHA.118.038881","journal-title":"Circulation"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of cardiorenal effects of sodium-glucose cotransporter\u00a02\u00a0inhibitors: JACC state-of-the-art review","volume":"75","author":"Zelniker TA","year":"2020","unstructured":"Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodium-glucose cotransporter\u00a02\u00a0inhibitors: JACC state-of-the-art review. J Am Coll Cardiol. 2020, 75:422-34. 10.1016\/j.jacc.2019.11.031","journal-title":"J Am Coll Cardiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.12.027","article-title":"Renoprotective effects of sodium-glucose cotransporter-2 inhibitors","volume":"94","author":"Heerspink HJ","year":"2018","unstructured":"Heerspink HJ, Kosiborod M, Inzucchi SE, Cherney DZ. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int. 2018, 94:26-39. 10.1016\/j.kint.2017.12.027","journal-title":"Kidney Int"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30384-5","article-title":"Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study","volume":"8","author":"Heerspink HJ","year":"2020","unstructured":"Heerspink HJ, Karasik A, Thuresson M, et al.. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. Lancet Diabetes Endocrinol. 2020, 8:27-35. 10.1016\/S2213-8587(19)30384-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-021-05407-5","article-title":"Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial","volume":"64","author":"Cherney DZ","year":"2021","unstructured":"Cherney DZ, Charbonnel B, Cosentino F, et al.. Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. Diabetologia. 2021, 64:1256-67. 10.1007\/s00125-021-05407-5","journal-title":"Diabetologia"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.030012","article-title":"Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials","volume":"136","author":"Lytvyn Y","year":"2017","unstructured":"Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZ. Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation. 2017, 136:1643-58. 10.1161\/CIRCULATIONAHA.117.030012","journal-title":"Circulation"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30182-1","article-title":"Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial","volume":"5","author":"Cherney DZ","year":"2017","unstructured":"Cherney DZ, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, von Eynatten M, Wanner C. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017, 5:610-21. 10.1016\/S2213-8587(17)30182-1","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2019.1601404","article-title":"SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence","volume":"131","author":"Davidson JA","year":"2019","unstructured":"Davidson JA. SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence. Postgrad Med. 2019, 131:251-60. 10.1080\/00325481.2019.1601404","journal-title":"Postgrad Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.10.020","article-title":"Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States","volume":"31","author":"Koro CE","year":"2009","unstructured":"Koro CE, Lee BH, Bowlin SJ. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin Ther. 2009, 31:2608-17. 10.1016\/j.clinthera.2009.10.020","journal-title":"Clin Ther"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01430-3","article-title":"SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs","volume":"20","author":"Giugliano D","year":"2021","unstructured":"Giugliano D, Longo M, Scappaticcio L, Bellastella G, Maiorino MI, Esposito K. SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs. Cardiovasc Diabetol. 2021, 20:236. 10.1186\/s12933-021-01430-3","journal-title":"Cardiovasc Diabetol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1080\/17446651.2019.1571908","article-title":"Fixed-dose combination of ertugliflozin and metformin hydrochloride for the treatment of type 2 diabetes","volume":"14","author":"Frias JP","year":"2019","unstructured":"Frias JP. Fixed-dose combination of ertugliflozin and metformin hydrochloride for the treatment of type 2 diabetes. Expert Rev Endocrinol Metab. 2019, 14:75-83. 10.1080\/17446651.2019.1571908","journal-title":"Expert Rev Endocrinol Metab"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S114932","article-title":"Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date","volume":"11","author":"Cinti F","year":"2017","unstructured":"Cinti F, Moffa S, Impronta F, et al.. Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date. Drug Des Devel Ther. 2017, 11:2905-19. 10.2147\/DDDT.S114932","journal-title":"Drug Des Devel Ther"},{"key":"ref28","unstructured":"FDA approves SGLT2 inhibitor STEGLATRO\u2122 (ertugliflozin) and fixed-dose combination STEGLUJAN\u2122 (ertugliflozin and sitagliptin) for adults with type 2 diabetes. (2017). https.\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/fda_approves_sglt2_inhibitor_steglatro_ertugliflozin_a...."},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-017-0358-0","article-title":"Ertugliflozin and sitagliptin co-initiation in patients with type 2 diabetes: the VERTIS SITA randomized study","volume":"9","author":"Miller S","year":"2018","unstructured":"Miller S, Krumins T, Zhou H, et al.. Ertugliflozin and sitagliptin co-initiation in patients with type 2 diabetes: the VERTIS SITA randomized study. Diabetes Ther. 2018, 9:253-68. 10.1007\/s13300-017-0358-0","journal-title":"Diabetes Ther"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.722","article-title":"Bioequivalence of ertugliflozin\/sitagliptin fixed-dose combination tablets and coadministration of respective strengths of individual components","volume":"8","author":"Fediuk DJ","year":"2019","unstructured":"Fediuk DJ, Matschke K, Liang Y, et al.. Bioequivalence of ertugliflozin\/sitagliptin fixed-dose combination tablets and coadministration of respective strengths of individual components. Clin Pharmacol Drug Dev. 2019, 8:884-94. 10.1002\/cpdd.722","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.7b00687","article-title":"Impact of the US FDA \"Biopharmaceutics Classification System\" (BCS) guidance on Global Drug Development","author":"Mehta MU","year":"2017","unstructured":"Mehta MU, Uppoor RS, Conner DP, et al.. Impact of the US FDA \"Biopharmaceutics Classification System\" (BCS) guidance on Global Drug Development. Mol Pharm. 2017, 14:4334-8. Accessed: February 2019: 10.1021\/acs.molpharmaceut.7b00687"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13194","article-title":"Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: the VERTIS FACTORIAL randomized trial","volume":"20","author":"Pratley RE","year":"2018","unstructured":"Pratley RE, Eldor R, Raji A, et al.. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: the VERTIS FACTORIAL randomized trial. Diabetes Obes Metab. 2018, 20:1111-20. 10.1111\/dom.13194","journal-title":"Diabetes Obes Metab"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13103","article-title":"Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)","volume":"20","author":"Rosenstock J","year":"2018","unstructured":"Rosenstock J, Frias J, P\u00e1ll D, et al.. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab. 2018, 20:520-9. 10.1111\/dom.13103","journal-title":"Diabetes Obes Metab"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-02733-w","article-title":"Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"7","author":"Liu J","year":"2017","unstructured":"Liu J, Li L, Li S, Jia P, Deng K, Chen W, Sun X. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. Sci Rep. 2017, 7:2824. 10.1038\/s41598-017-02733-w","journal-title":"Sci Rep"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13116","article-title":"Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: the VERTIS SITA2 placebo-controlled randomized study","volume":"20","author":"Dagogo-Jack S","year":"2018","unstructured":"Dagogo-Jack S, Liu J, Eldor R, et al.. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: the VERTIS SITA2 placebo-controlled randomized study. Diabetes Obes Metab. 2018, 20:530-40. 10.1111\/dom.13116","journal-title":"Diabetes Obes Metab"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/110707-role-of-ertugliflozin-in-the-management-of-diabetes-mellitus","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:41:11Z","timestamp":1707507671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/110707-role-of-ertugliflozin-in-the-management-of-diabetes-mellitus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,12]]},"references-count":35,"URL":"https:\/\/doi.org\/10.7759\/cureus.31404","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,12]]}}}